Protalex (PRTX) Stock Price, News & Analysis

Company Overview

Protalex, Inc. (OTCMKTS: PRTX) is a development‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company was founded in 2006 with a focus on harnessing the body’s immune system to target and eliminate cancer cells. Protalex leverages proprietary antibody engineering and fusion protein technologies to create multi‐functional immunotherapies designed to stimulate antitumor T‐cell responses.

At the core of Protalex’s pipeline are novel fusion proteins and bispecific antibody constructs that bridge tumor antigens with costimulatory immune receptors. These candidates are engineered to engage key pathways in the tumor microenvironment, including CD28 and other costimulatory molecules, with the goal of enhancing T‐cell activation while minimizing off‐target effects. The company’s research efforts span both solid tumors and hematologic malignancies, with several preclinical programs advancing toward IND‐enabling studies.

Protalex collaborates with academic institutions and research organizations to validate its platform and identify new therapeutic targets. Its management team brings together expertise in protein engineering, oncology drug development and regulatory strategy. While operating primarily in North America, the company seeks to establish broader partnerships to support global clinical development and, ultimately, commercialization of its immuno‐oncology candidates.

Key Stats

• Today's Range: $0.0130 to $0.0130
• 50-Day Range: $0.0130 to $0.0130
• 52-Week Range: $0.00 to $0.10
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PRTX Stock Analysis - Frequently Asked Questions

How have PRTX shares performed this year?

Protalex's stock was trading at $0.0130 at the beginning of 2025. Since then, PRTX shares have increased by 0.0% and is now trading at $0.0130.

How were Protalex's earnings last quarter?

Protalex Inc. (OTCMKTS:PRTX) released its earnings results on Friday, April, 13th. The company reported ($0.06) earnings per share for the quarter.

How do I buy shares of Protalex?

Shares of PRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Protalex own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Protalex investors own include Boeing (BA), Caterpillar (CAT), Enterprise Products Partners (EPD), Eros STX Global (EROS), Global Payments (GPN), Intuitive Surgical (ISRG) and AT&T (T).

Company Calendar

• Last Earnings: 4/13/2018
• Today: 10/20/2025
• Fiscal Year End: 5/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Business Services
• Current Symbol: OTCMKTS:PRTX
• Previous Symbol: NASDAQ:PRTX
• CIK: 1099215
• Web: www.protalex.com
• Phone: 215-862-9720
• Fax: 215-862-6614
• Employees: 2
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A